机构：[a]Department of Thoracic Oncology, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China,四川大学华西医院[b]Department of Medical Oncology, Sichuan Cancer Hospital &institute & School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院四川省肿瘤医院[c]Department of General Internal Medicine, Sichuan Cancer Hospital &institute & School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院四川省肿瘤医院[d]Department of Pathology, Sichuan Cancer Hospital &institute & School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院四川省肿瘤医院[e]Ward 1, Department of Thoracic Surgery, Sichuan Cancer Hospital &institute & School of Medicine, University of Electronic Science and Technology of China, Chengdu, China外科中心胸外科中心四川省人民医院四川省肿瘤医院胸外科
Non-small cell lung cancer (NSCLC) is the highest incidence and mortality of malignant tumors worldwide and has become a global public health problem. Long non-coding RNAs (LncRNAs) are expected to participate in the progression of NSCLC. This study aims to explore the effects and underlying mechanisms of LncRNA HOXC-AS2 on NSCLC cell proliferation, apoptosis, and migration. The Cell Counting Kit-8 (CCK-8) and clone formation assay were used to measure the A549 and HCC827 cell proliferation. The cell apoptosis and migration was respectively analyzed by flow cytometry and transwell assay. RNA immunoprecipitation (RIP) was used to detect the interaction between HOXC-AS2 and HOXC13. The expression of beta-catenin, alpha-SMA, MMP-1, MMP-2 expression, E-cadherin, and Ki-67 expression were determined by Western blot or immunohistochemistry (IHC) assay. We found that HOXC-AS2 was significantly up-regulated in NSCLC tissues. Knockdown of HOXC-AS2 expression resulted in significant decreases in NSCLC cell proliferation, migration, and epithelial-mesenchymal transition (EMT) process marker proteins, simultaneously activated A549 and HCC827 cell apoptosis. RIP assay suggested that HOXC13 was a functional target for HOXC-AS2. And HOXC-AS2 and HOXC13 could positively regulate each other. Compared with the normal tissues, the mRNA level of HOXC13 was increased in NSCLC tissues. HOXC13 silencing counteracted increases of A549 and HCC827 cell proliferation and migration, as well as a decrease of cell apoptosis induced by HOXC-AS2 overexpression. Moreover, HOXC-AS2 silencing reduced tumor growth rate and Ki-67 expression in vivo. Taken together, HOXC-AS2 knockdown inhibited NSCLC cell proliferation and migration, as well as stimulated NSCLC cell apoptosis through regulation of HOXC13 expression.
基金：
National Major Science and Technology Projects of China [2017ZX09304023]
第一作者机构：[a]Department of Thoracic Oncology, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China,[b]Department of Medical Oncology, Sichuan Cancer Hospital &institute & School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Bin Liu,Jing Li,Ji-Man Li,et al.HOXC-AS2 mediates the proliferation, apoptosis, and migration of non-small cell lung cancer by combining with HOXC13 gene[J].CELL CYCLE.2021,20(2):236-246.doi:10.1080/15384101.2020.1868161.
APA：
Bin Liu,Jing Li,Ji-Man Li,Guang-Yuan Liu&Yong-Sheng Wang.(2021).HOXC-AS2 mediates the proliferation, apoptosis, and migration of non-small cell lung cancer by combining with HOXC13 gene.CELL CYCLE,20,(2)
MLA：
Bin Liu,et al."HOXC-AS2 mediates the proliferation, apoptosis, and migration of non-small cell lung cancer by combining with HOXC13 gene".CELL CYCLE 20..2(2021):236-246
